Related references
Note: Only part of the references are listed.Visualization of self-delivering hydrophobically modified siRNA cellular internalization
Socheata Ly et al.
NUCLEIC ACIDS RESEARCH (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity (vol 43, pg 2993, 2015)
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2017)
5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
Reka A. Haraszti et al.
NUCLEIC ACIDS RESEARCH (2017)
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
Jayaprakash K. Nair et al.
NUCLEIC ACIDS RESEARCH (2017)
Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay
Bruno M. D. C. Godinho et al.
NUCLEIC ACID THERAPEUTICS (2017)
A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons in vitro with Oligonucleotide Therapeutics
Julia F. Alterman et al.
BIO-PROTOCOL (2017)
Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-L-serine siRNA Conjugate in Mouse Brain
Mehran Nikan et al.
BIOCONJUGATE CHEMISTRY (2017)
Synergistic effect of phosphorothioate, 5′-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA
Thazha P. Prakash et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
9 5′-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates
Rubina Parmar et al.
CHEMBIOCHEM (2016)
Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide
Nicole T. Schirle et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo
Andrew H. Coles et al.
NUCLEIC ACID THERAPEUTICS (2016)
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth
Tayeba Khan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain
Mehran Nikan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides
William E. Salomon et al.
CELL (2015)
Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs
Maire F. Osborn et al.
NUCLEIC ACIDS RESEARCH (2015)
Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain
Julia F. Alterman et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
Trinna L. Cuellar et al.
NUCLEIC ACIDS RESEARCH (2015)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
James E. Dahlman et al.
NATURE NANOTECHNOLOGY (2014)
Structural basis for microRNA targeting
Nicole T. Schirle et al.
SCIENCE (2014)
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Fritz Eckstein
NUCLEIC ACID THERAPEUTICS (2014)
Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye
Michael Byrne et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2013)
The 5′ Binding MID Domain of Human Argonaute2 Tolerates Chemically Modified Nucleotide Analogues
Glen F. Deleavey et al.
NUCLEIC ACID THERAPEUTICS (2013)
Argonaute Divides Its RNA Guide into Domains with Distinct Functions and RNA-Binding Properties
Liang Meng Wee et al.
CELL (2012)
Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression
Dongbo Yu et al.
CELL (2012)
Single-Stranded siRNAs Activate RNAi in Animals
Walt F. Lima et al.
CELL (2012)
Silencing disease genes in the laboratory and the clinic
Jonathan K. Watts et al.
JOURNAL OF PATHOLOGY (2012)
Defined Folate-PEG-siRNA Conjugates for Receptor-specific Gene Silencing
Christian Dohmen et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Unique Gene-Silencing and Structural Properties of 2 '-Fluoro-Modified siRNAs
Muthiah Manoharan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery
Qingmin Chen et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Transfection Techniques for Neuronal Cells
Daniela Karra et al.
JOURNAL OF NEUROSCIENCE (2010)
Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing
Glen F. Deleavey et al.
NUCLEIC ACIDS RESEARCH (2010)
Chemically modified siRNA: tools and applications
Jonathan K. Watts et al.
DRUG DISCOVERY TODAY (2008)
Efficient in vivo delivery of siRNA to the liver by conjugation of α-tocopherol
Kazutaka Nishina et al.
MOLECULAR THERAPY (2008)
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Christian Wolfrum et al.
NATURE BIOTECHNOLOGY (2007)
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
David B. Rozema et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras
James O. McNamara et al.
NATURE BIOTECHNOLOGY (2006)
Position-specific chemical modification of siRNAs reduces off-target'' transcript silencing
Aimee L. Jackson et al.
RNA (2006)
Chemical modification of siRNAs to improve serum stability without loss of efficacy
S Choung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo
AD Judge et al.
MOLECULAR THERAPY (2006)
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes
C Matranga et al.
CELL (2005)
Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA
CR Allerson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
F Czauderna et al.
NUCLEIC ACIDS RESEARCH (2003)
Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in-vivo
CR Dass et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
Share Paper
